Clinical Trial Update: E7 TCR T Cells for Human Papillomavirus-Associated Cancers [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial of E7 TCR T cells for human papillomavirus–associated cancers has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Carcinoma in Situ
• Cervical Intraepithelial Neoplasia
• Human Papillomavirus Infection
• Vulvar Diseases
• Vulvar Neoplasms

Drugs mentioned

• E7 TCR T cells

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Papillomavirus Infections, Cervical Intraepithelial Neoplasia | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2026-03-09